As the only pharmaceutical company solely focused on HIV/AIDS, ViiV Healthcare takes a holistic approach to ending the HIV epidemic. We research, develop and deliver innovative medicines and solutions that make a difference to people living with or seeking to prevent HIV and AIDS.
St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital is a National Cancer Institute (NCI)–designated Comprehensive Cancer Center devoted solely to children. Our 300 faculty work across the spectrum of basic, translational, clinical, and population science in a highly collaborative multidisciplinary environment that includes a Nobel laureate and members of the National Academy of Science and the National Academy of Medicine. St. Jude is ranked on Fortune Magazine’s “Best Workplaces in Health Care & Biopharma” and Glassdoor’s “Best Places to Work,” and is located in the heart of Memphis, Tennessee, a vibrant and friendly city at the historic American crossroads of music, trade, food and culture. At St. Jude, we have one common goal: find cures for children with cancer and other life-threatening diseases through research and treatment. As both a world-class research institute and a specialized children’s hospital, St. Jude provides an unparalleled opportunity to advance your scientific training and launch your career. | St. Jude Children’s Research Hospital is a global leader in the research and treatment of pediatric cancer and other life-threatening diseases of childhood. Headquartered in Memphis, Tennessee, St. Jude is the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. St. Jude has been named a top pediatric cancer hospital on U.S. News & World Report’s annual “Best Hospitals” list and named to Fortune magazine’s “100 Best Companies to Work For” list. Research and treatments developed at St. Jude are shared to help improve the survival rate for children with cancer and other life-threatening diseases worldwide. St. Jude is recognized as one of the world’s premier pediatric research and treatment institutions with a focus on acute lymphoblastic leukemia, brain tumors and infectious diseases. With eight affiliate clinics across the country, St. Jude treats about 8,600 children each year. Beyond the United States, the institution’s St. Jude Global initiative seeks to improve health care for children with life-threatening disease worldwide. The goal of the Department of Infectious Diseases at St. Jude Children’s Research Hospital is to study devastating diseases of childhood through a comprehensive approach including basic science research, translational trials, and bedside care. Among the top infectious causes of death worldwide are respiratory diseases and HIV/AIDS. The Department of Infectious Diseases seeks to focus on the pathogenesis of these infections with a breadth of commitment that extends from the research bench to the bedside. Investigations take place at progressive levels: manipulation of genes is expected to lead to phenotypes in cell culture systems that can be modeled in animal studies. Therapeutic candidates in the form of antimicrobials, vaccines, or adjunctive therapies are further pursued in clinical trials in children. Follow us to discover the research, scientific discoveries, clinical care and employment opportunities at St. Jude. View our career opportunities: www.stjude.org/JoinOurMission. Follow St. Jude across social media at @stjuderesearch.
Sanofi Global
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company’s more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com. | Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company’s nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com. Invitae is a part of Labcorp. | We are a global life sciences and healthcare company harnessing science for human good. Every day, our mission is to improve health and improve lives. | Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company’s nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at https://www.labcorp.com/infectious-disease.
Invivyd
Invivyd is developing antibodies to transcend the limits of naturally occurring immunity and provide higher levels of protection from viral diseases, beginning with COVID-19
Diasorin
TRANSFORMING HEALTH MANAGEMENT THROUGH MEANINGFUL DIAGNOSTICS Diasorin is a global leader in specialty testing, advancing infectious disease diagnostics with innovative, high-quality molecular and immunodiagnostic solutions. For over 50 years, Diasorin has delivered trusted results that empower clinicians and laboratories worldwide to optimize patient outcomes. With more than 40 first-to-market tests, Diasorin continues to set the standard for diagnostic innovation and reliability. The LIAISON PLEX® Respiratory Flex Assay, run on our LIAISON PLEX® System, is driven by Flex™ Testing, which enables you to report targeted custom panels selected from a larger list of 19 viruses and bacteria. This customizable approach helps reduce unnecessary testing, ultimately saving on costs while allowing you to address the specific needs of your patient population and seasonal trends. Our newly launched LIAISON PLEX® Bloodstream Infection (BSI) portfolio aids in the fight against sepsis by detecting 48 key bacterial and yeast pathogens, along with 12 crucial antimicrobial resistance genes associated with bloodstream infections and sepsis. The LIAISON PLEX® BSI portfolio comprises the LIAISON PLEX® Gram-Positive (BCP) Assay, LIAISON PLEX® Gram-Negative (BCN) Assay, and LIAISON PLEX® Yeast Blood Culture (BCY) Assay, and supports timely, informed clinical decisions, aiding in the optimization of patient management while reinforcing antimicrobial stewardship. Additionally, our Simplexa® C. auris Direct is a real-time PCR assay and part of the expanding assay portfolio performed on the LIAISON® MDX instrument. Intended for patients suspected of Candida auris colonization, Simplexa® C. auris Direct is the only FDA authorized test supporting prevention and control efforts in healthcare settings, addressing the critical gap in the molecular detection of C. auris colonization. Beyond molecular solutions, Diasorin offers one of the broadest immunodiagnostic portfolios in infectious disease testing, consolidated on the fully automated LIAISON® family of analyzers. With menu breadth covering routine to highly specialized assays, Diasorin enables laboratories to streamline workflows, close diagnostic gaps, and deliver high-impact results with confidence. From routine screening to complex diagnostic challenges—especially amid rising outbreaks, emerging threats, and declining vaccination rates—Diasorin provides the accuracy, efficiency, and reliability healthcare professionals can depend on for the right test, every time.
Clarametyx Biosciences
Clarametyx Biosciences is combating the formidable challenge of chronic respiratory diseases through an innovative technology platform targeting bacterial biofilms. The Columbus, Ohio-based company is building a pipeline of immune-enabling medicines, including CMTX-101, which completed a positive Phase 2 study in cystic fibrosis patients in early 2026, and plans to pursue additional mid-stage studies in other chronic respiratory diseases including bronchiectasis. The company’s second program, CMTX-301, is in early development to evaluate the technology in a preventive approach. | Clarametyx Biosciences is combating the formidable challenge of chronic, recalcitrant respiratory disease decline through an innovative technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response and antibiotic intervention. The Columbus, Ohio-based company is building a pipeline of immune-enabling therapies and vaccines, including CMTX-101, which is in a Phase 2a study for infections associated with cystic fibrosis, and CMTX-301, an anti-biofilm vaccine in early development.
Bruker
Bruker’s MALDI Biotyper®, the market-leading MALDI-TOF for microbial identification, revolutionized microbiology by providing an identification for over 4000 species in less than 10 minutes starting from culture. Another Bruker innovation, the IR Biotyper®, provides rapid and cost-effective microorganism strain typing using infrared spectroscopy technology to further support proactive infection control. ELITechGroup MDx — a Bruker Company offers a complete portfolio of molecular diagnostics products, including infectious disease reagents and sample-to-result instruments. | Bruker is a performance leader in life science and analytical systems. For over 50 years, Bruker has been driven by a single idea: to provide the best technological solution for each analytical task. Our trusted solutions encompass a wide number of analytical techniques including Mass Spectrometry, Optical and X-Ray Spectroscopy. These market and technology leading products are driving and facilitating success in the food industry. | Bruker is a pioneering scientific solutions provider, advancing the standards in high-performance analytical instruments. We specialize in FT-NIR (Fourier Transform Near-Infrared) spectroscopy for feed and ingredient analysis. Our solutions are designed to help labs improve the quality of their animal feed by providing accurate, real-time data on nutrient content. We use advanced FT-NIR technology to perform comprehensive analysis on a wide range of feeds and raw materials, identifying key nutritional metrics such as protein, fat, moisture, fiber, ash, amino acids, and more. The results from our sophisticated spectroscopy technology enable labs to adjust their feed compositions for optimal animal health and productivity. | Bruker offers advanced solutions to reliably support geologists and mining prospectors on locating and analyzing deposits anytime and anywhere. So it is no wonder that Bruker’s instruments can be found at an altitude of 4,000 meters or in baking hot deserts – reliably delivering high end analysis quickly and on-site. | The performance of any battery, whether in terms of its capacity, lifetime or energy density, is ultimately down to the intrinsic properties of the materials that comprise its anode, cathode, electrolyte and SEI. Bruker has developed a comprehensive suite of characterization techniques to enable scientist to understand and optimize the physical and chemical properties, performance and stability of all battery components and the fully assembled battery cells. | Discover what you can achieve in battery research and manufacturing with a range of advanced technologies. From investigating solutes and electrodes to monitoring battery cell behavior and conducting in situ research on energy storage materials, Bruker scientists will share a wealth of knowledge with you.
Biocodex
Since 1953, Biocodex teams have been passionately committed to a single mission: providing innovative healthcare solutions to women, men and children worldwide. With over 1,600 employees, Biocodex is committed to serving millions of people around the world. Biocodex USA markets Florastor® daily probiotic, (Saccharomyces boulardii CNCM I-745®) that supports digestive balance and strengthens the immune system. Florastor is the only probiotic in North America to contain the original and exclusive yeast strain, S. boulardii CNCM I-745, supported by over 70 years of research, over 1,000 publications, more than 130 clinical studies and over 13 meta-analyses. Unlike most bacteria-based probiotics, Florastor is naturally resistant to antibiotics and therefore can be taken at the same time to enhance patient compliance.